RaySearch Laboratories AB (publ) Interim Report January 1 - September 30, 2008

RaySearch Laboratories AB (publ) Interim Report January 1 - September 30, 2008

JANUARY 1 - SEPTEMBER 30, 2008 
• Net sales for the period amounted to SEK 41.3 M (50.2) 
• Profit after tax was SEK 7.3 M (16.8) 
• Earnings per share amounted to SEK 0.21 (0.49)
• Operating profit amounted to SEK 8.0 M (22.1)
• Cash flow from operating activities amounted to SEK 6.8 M (25.7)
• Agreement with Philips covering new product within the revolutionary VMAT
treatment method reached in June 
• Agreement regarding a treatment planning system for proton therapy at Uppsala
University Hospital secured in August.
• Agreement covering research cooperation within multi-criteria optimization
with Massachusetts General Hospital in Boston, Massachusetts, in the US signed
in August.

“Sales during the third quarter declined compared with the same period in the
preceding year, but we are seeing a positive trend from the second to the third
quarter this year. The sales volume through Philips rebounded from the unusually
low level during the second quarter, while at the same time the USD
strengthened, which combined resulted in a sales increase of 14 percent from the
second to the third quarter,” says Johan Löf, President of RaySearch.

“The global financial crisis is obviously a potential concern. We are monitoring
market developments closely but historically the market for radiation therapy
products has been relatively insensitive to economic trends. We are currently
not making any changes in our business due to the uncertain market situation,
but continue to focus on completing the large number of contracted products that
are to be launched in the quarters ahead.”

“At the same time we are actively involved in a number of discussions about new
products with new and existing partners. Therefore, despite our profitability
being relatively low at the moment and the financial crisis sweeping across the
globe, there are good reasons to view RaySearch's future positively,” concludes
Johan Löf.

FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf, President and CEO
Tel: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com

RaySearch Laboratories AB (publ)
Corp. Reg. No: 556322-6157
Sveavägen 25
SE-111 34 Stockholm 
Sweden

ABOUT RAYSEARCH
RaySearch Laboratories is a medical technology company that develops advanced
software solutions for improved radiation therapy of cancer. RaySearch's
products are sold through license agreements with leading partners such as
Philips, Varian, Nucletron, IBA Dosimetry and TomoTherapy. Eight products have
been released to date and RaySearch's software is used at over 1,300 clinics in
more than 30 countries. In addition, existing license agreements cover more than
15 other products that are scheduled to be launched in the coming years.
RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in
Stockholm and the company is listed in the SmallCap segment on the OMX Nordic
Exchange Stockholm. 

For more information about RaySearch, visit www.raysearchlabs.com.